+

WO2002019995A3 - Utilisation d'une combinaison pharmaceutique - Google Patents

Utilisation d'une combinaison pharmaceutique Download PDF

Info

Publication number
WO2002019995A3
WO2002019995A3 PCT/GB2001/004001 GB0104001W WO0219995A3 WO 2002019995 A3 WO2002019995 A3 WO 2002019995A3 GB 0104001 W GB0104001 W GB 0104001W WO 0219995 A3 WO0219995 A3 WO 0219995A3
Authority
WO
WIPO (PCT)
Prior art keywords
fluticasone
pharmaceutical combination
combination containing
containing salmeterol
salmeterol
Prior art date
Application number
PCT/GB2001/004001
Other languages
English (en)
Other versions
WO2002019995A2 (fr
Inventor
Smithkline Glaxo
Original Assignee
Glaxo Group Ltd
Smithkline Glaxo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Smithkline Glaxo filed Critical Glaxo Group Ltd
Priority to AU2001284287A priority Critical patent/AU2001284287A1/en
Publication of WO2002019995A2 publication Critical patent/WO2002019995A2/fr
Publication of WO2002019995A3 publication Critical patent/WO2002019995A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation de combinaisons de salmétérol et de propionate de fluticasone pour la prévention et le traitement des rhinites.
PCT/GB2001/004001 2000-09-07 2001-09-06 Utilisation d'une combinaison pharmaceutique WO2002019995A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001284287A AU2001284287A1 (en) 2000-09-07 2001-09-06 Pharmaceutical combination containing salmeterol and fluticasone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021927.9A GB0021927D0 (en) 2000-09-07 2000-09-07 Use of pharmaceutical combination
GB0021927.9 2000-09-07

Publications (2)

Publication Number Publication Date
WO2002019995A2 WO2002019995A2 (fr) 2002-03-14
WO2002019995A3 true WO2002019995A3 (fr) 2002-08-22

Family

ID=9899002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004001 WO2002019995A2 (fr) 2000-09-07 2001-09-06 Utilisation d'une combinaison pharmaceutique

Country Status (3)

Country Link
AU (1) AU2001284287A1 (fr)
GB (1) GB0021927D0 (fr)
WO (1) WO2002019995A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416925A2 (fr) * 1989-09-07 1991-03-13 Glaxo Group Limited Utilisation du 4-hydroxy-alpha 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol ou ses sels dans le traitement de l'allergie et de l'inflammation
WO1997046243A1 (fr) * 1996-06-04 1997-12-11 The Procter & Gamble Company Aerosol nasal contenant un steroide intranasal et un antihistaminique
WO1998017676A1 (fr) * 1996-10-24 1998-04-30 Glaxo Group Limited Nouvelle forme cristalline polymorphe de propionate de fluticasone, son procede de production et des compositions pharmaceutiques la renfermant
WO2001028535A2 (fr) * 1999-10-21 2001-04-26 Glaxo Group Limited Formulations pharmaceutiques
WO2001047493A1 (fr) * 1999-12-24 2001-07-05 Glaxo Group Limited Formulation pharmaceutique en aerosol de salmeterol et de propionate de fluticasone

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416925A2 (fr) * 1989-09-07 1991-03-13 Glaxo Group Limited Utilisation du 4-hydroxy-alpha 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol ou ses sels dans le traitement de l'allergie et de l'inflammation
WO1997046243A1 (fr) * 1996-06-04 1997-12-11 The Procter & Gamble Company Aerosol nasal contenant un steroide intranasal et un antihistaminique
WO1998017676A1 (fr) * 1996-10-24 1998-04-30 Glaxo Group Limited Nouvelle forme cristalline polymorphe de propionate de fluticasone, son procede de production et des compositions pharmaceutiques la renfermant
WO2001028535A2 (fr) * 1999-10-21 2001-04-26 Glaxo Group Limited Formulations pharmaceutiques
WO2001047493A1 (fr) * 1999-12-24 2001-07-05 Glaxo Group Limited Formulation pharmaceutique en aerosol de salmeterol et de propionate de fluticasone

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENINCASA C ET AL: "EVALUATION OF FLUTICASONE PROPIONATE AQUEOUS NASAL SPRAY TAKEN ALONE AND IN COMBINATION WITH CETIRIZINE IN THE PROPHYLACTIC TREATMENT OF SEASONAL ALLERGIC RHINITIS", DRUG INVESTIGATION, ADIS INTERNATIONAL, NZ, vol. 8, no. 4, 1994, pages 225 - 233, XP000651434, ISSN: 0114-2402 *
MANCINI V ET AL: "FLUTICASONE PROPIONATE OR BUDESONIDE WITH SALMETEROL IN BRONCHIAL SEVERE ASTHMA IN PEDIATRIC AGE", ALLERGY, MUNSKGAARD, COPENHAGEN, DK, vol. 53, no. SUPPL 43, 25 June 1998 (1998-06-25), pages 185, XP001013216, ISSN: 0105-4538 *
MARKHAM A ET AL: "INHALED SALMETEROL/FLUTICASONE PROPIONATE COMBINATION A REVIEW OF ITS USE IN PERSISTENT ASTHMA", DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 60, no. 5, November 2000 (2000-11-01), pages 1207 - 1233, XP001013660, ISSN: 0012-6667 *
PALMQVIST M ET AL: "ONSET OF BRONCHODILATION OF BUDESONIDE/FORMOTEROL VS SALMETEROL/FLUTICASONE IN SINGLE INHALERS", PULMONARY PHARMACOLOGY AND THERAPEUTICS, ACADEMIC PRESS, NEW YORK, NY, US, vol. 14, no. 1, 2001, pages 29 - 34, XP001013120, ISSN: 1094-5539 *
PUHAKKA T ET AL: "Sinusitis in the common cold.", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. UNITED STATES SEP 1998, vol. 102, no. 3, September 1998 (1998-09-01), pages 403 - 408, XP001079208, ISSN: 0091-6749 *
RATNER P H ET AL: "A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis", JOURNAL OF FAMILY PRACTICE, NEW YORK, NY, US, vol. 47, no. 2, August 1998 (1998-08-01), pages 118 - 125, XP002121956, ISSN: 0094-3509 *

Also Published As

Publication number Publication date
WO2002019995A2 (fr) 2002-03-14
GB0021927D0 (en) 2000-10-25
AU2001284287A1 (en) 2002-03-22

Similar Documents

Publication Publication Date Title
IL196301A0 (en) Medicament for the treatment of hapatitis c
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
HUP0402629A3 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2001022955A3 (fr) Nouvelle association de loteprednol et de produits antihistaminiques
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
WO2002017894A3 (fr) Utilisation d'une combinaison de salmeterol et de propionate de fluticasone
WO2002039997A3 (fr) Composes modulant ace-2 et procedes d'utilisation associes
AU2001293891A1 (en) New combination for the treatment of asthma
WO2001076601A3 (fr) Compositions pharmaceutiques
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
WO2002069979A3 (fr) Preparations pharmaceutiques
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
WO2001028535A3 (fr) Formulations pharmaceutiques
AU2003291368A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
WO2002019995A3 (fr) Utilisation d'une combinaison pharmaceutique
WO2002083700A3 (fr) Disaccharides hypersulfates et leur utilisation en traitement contre les inflammations
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载